TFRC and non-small cell lung carcinoma: Liposomes loaded with the anti-cancer drug, gefitinib, and cholesterol-lowering drug, simvastatin, conjugated with T12, a peptide specific to TfR, and a nanobody specific to a tumour-associated macrophage marker, PD-L1, have been demonstrated to engage the TfR, cross the BBB, and then target tumour-associated macrophages in mice with an intracranial transplant of non-small lung cell cancer cells [72].